Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15449193 | 0.85 | FAAH (0.35) | FAAHCNR1CNR2MEN1CYP2C19 | |
| SCHEMBL17231635 | 0.82 | MMP1 (0.44) | FAAHCNR1CNR2 | |
| SCHEMBL18823277 | 0.82 | FAAH (0.33) | FAAHCNR1CNR2 | |
| SCHEMBL28737699 | 0.81 | RIPK1 (0.32) | FAAH | |
| SCHEMBL14296150 | 0.79 | MEN1 (0.34) | FAAHCNR1CNR2MEN1CYP2C19 | |
| SCHEMBL880131 | 0.79 | FAAH (0.44) | FAAHCNR1CNR2MEN1CYP2C19 | |
| SCHEMBL30547117 | 0.79 | FAAH (0.44) | FAAHCNR1CNR2MEN1CYP2C19 | |
| SCHEMBL17461876 | 0.78 | FAAH (0.35) | FAAH | |
| SCHEMBL17461877 | 0.78 | FAAH (0.35) | FAAH | |
| SCHEMBL28022900 | 0.77 | GRN (0.35) | MEN1CYP2C19RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9808528-B2 | Protein-polymer-drug conjugates and methods of using same | MERSANA THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MERSANA THERAPEUTICS, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | FAAH 4244/4885CNR1 3503/4885CNR2 3843/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | FAAH 4244/4885CNR1 3503/4885CNR2 3843/4885 |
| US-20140017265-A1 | Terminally Modified Polymers and Conjugates Thereof | MALT1, ALG1, PRMT3 | FAAH 4461/4885CNR1 617/4885CNR2 1006/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | FAAH 3304/4885CNR1 4476/4885CNR2 4551/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | FAAH 3922/4885CNR1 2740/4885CNR2 3207/4885 |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | FAAH 3674/4885CNR1 3655/4885CNR2 3893/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | FAAH 3193/4885CNR1 4584/4885CNR2 4628/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | FAAH 3867/4885CNR1 2580/4885CNR2 3063/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | FAAH 3689/4885CNR1 3639/4885CNR2 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.